AI for Biology

Snapshot

AI for Biology is the application of machine learning and foundation-model techniques to biological data, experimental design, molecular engineering, diagnostics, and therapeutic development. It is becoming a distinct category as large-scale biological datasets, specialized models, automated laboratories, and biotech capital converge.
ℹ️
“In 2025, AI-ML drug discovery and licensing attracted 348 financing rounds totaling $11 billion, versus 264 rounds and $8.9 billion in 2024.” [1]
This profile captures the category’s formation through 2025 and early 2026. The category is worth tracking because it sits at the intersection of AI infrastructure, life-science R&D, software-enabled laboratories, and therapeutics—markets with different buyers, development timelines, and definitions of success.

What is this Market Category?

AI for Biology comprises software, models, data platforms, and integrated laboratory systems that use machine learning to represent, predict, design, or optimize biological systems. Core applications include protein and antibody design, molecular-property prediction, drug-target identification, pathology and imaging analysis, genomics, RNA biology, biomarker discovery, and experimental planning. Customers include pharmaceutical companies, biotechnology companies, academic laboratories, contract research organizations, diagnostics providers, and increasingly industrial-biotechnology companies.
The category excludes conventional laboratory automation without a meaningful computational-intelligence layer, ordinary bioinformatics tools that do not materially use modern machine learning, and pharmaceutical companies that merely use AI internally without selling an AI-enabled product or platform. It also excludes generic enterprise AI software unless the product is specifically trained, validated, or integrated for biological workflows.
The boundary is disputed at the edges: some operators include AI-designed therapeutics and automated wet labs, while others reserve “AI for Biology” for reusable models and infrastructure rather than individual drug programs. Foundation-model companies themselves often frame the market broadly—from molecular data to organismal biology—whereas investors frequently analyze the narrower AI-drug-discovery segment. [2] [3]

Why Now?

  • Biological data and model scale have crossed a practical threshold. New companies are training foundation models on pathology images, protein sequences, molecular spectra, DNA, RNA, and other modalities; Bioptimus describes its objective as a universal biology model, while its H-optimus-0 model targets pathology. [2] [4]
  • Protein and molecular design are becoming interactive software workflows. Latent Labs launched LatentX as a browser-based system for designing novel proteins, making model access available to academic institutions, biotech startups, and pharmaceutical companies rather than only specialized computational teams. [5]
  • Capital formation has validated the category. Isomorphic Labs raised $600 million in its first external financing, led by Thrive Capital, demonstrating that investors are willing to fund AI-native drug-discovery platforms at a scale previously associated with major biotech companies. [6]
  • Specialist foundation-model startups can now assemble differentiated biological data and talent. Latent Labs emerged from stealth with $50 million, including a $40 million Series A co-led by Radical Ventures and Sofinnova Partners. [7]
  • AI is moving from prediction toward closed-loop experimentation. The investment thesis increasingly combines models, proprietary data, and laboratory execution; the resulting businesses aim not merely to annotate biology but to design experiments, generate candidates, and learn from experimental outcomes. This broader automation thesis is reflected in capital flowing to companies such as Lila Sciences and other AI–robotics platforms. [1]

What's Happening?

CAGR and TAM

  • Publicly available search results do not provide a sufficiently reliable, directly accessible market-report source for a defensible standalone AI-for-Biology CAGR or TAM. The available evidence is stronger for the narrower AI-drug-discovery financing market than for the entire category.
  • The most concrete current momentum figure is financing activity: AI-ML drug discovery and licensing reached $11 billion across 348 rounds in 2025, up from $8.9 billion across 264 rounds in 2024. [1]
  • The $11 billion financing figure is not a market-revenue estimate; it is a deal-flow measure covering AI/ML drug discovery, licensing, venture funding, and related transactions. It should not be substituted for category TAM or software revenue. [1]

Category creation events

  • Isomorphic Labs’ $600 million financing was a defining validation event: the Google DeepMind-linked company raised its first external round to build an AI-first drug-discovery platform. [6]
  • Latent Labs’ emergence from stealth crystallized a distinct “programmable biology” thesis, pairing a $50 million financing announcement with foundation models aimed at biology rather than generic scientific computing. [7] [8]
  • Bioptimus’ foundation-model trajectory helped establish a separate “AI foundation models for biology” subcategory: the company reported $76 million in total funding and released H-optimus-0 for pathology. [2] [4]

Capital concentration

  • Capital is concentrating in a small group of platform-scale companies. Isomorphic Labs raised $600 million in its first external round, while Pathos AI raised $365 million in Series D financing and Lila Sciences raised more than $500 million, according to a 2025 sector review. [6] [1]
  • Foundation-model financing is also substantial: Bioptimus reached $76 million, including a $41 million round led by Cathay Innovation, while Latent Labs raised $50 million, including a $40 million Series A co-led by Radical Ventures and Sofinnova Partners. [7] [2]
  • The funding pattern favors businesses that combine proprietary biological data, reusable models, and downstream therapeutic or laboratory applications. The market is therefore bifurcating between horizontal biology-model platforms and vertically integrated companies that use AI to advance their own drug pipelines. [2] [6] [1]

Market Incumbents

  • Alphabet / Google DeepMind — supplies foundational AI research and has incubated Isomorphic Labs, an AI-first drug-discovery company. [6]
  • NVIDIA — provides accelerated computing, scientific-AI infrastructure, and bioinformatics tooling used by life-science researchers and developers.
  • Microsoft — offers cloud, AI, data, and genomics infrastructure to healthcare and life-science organizations.
  • Amazon Web Services — provides cloud compute, machine learning, and data infrastructure for pharmaceutical and biotechnology workloads.
  • IBM — participates in computational biology through enterprise AI, scientific computing, and quantum-computing research.
  • Oracle — supplies enterprise data and cloud infrastructure to pharmaceutical, clinical, and healthcare organizations.
  • Thermo Fisher Scientific — owns a major life-science tools and services footprint that can incorporate AI into instruments, analysis, and research workflows.

Alphabet / Google DeepMind

Stage : public (NASDAQ: GOOGL) Funding : Alphabet’s market capitalization and consolidated revenue are reported at the parent-company level; Isomorphic Labs raised $600 million in its first external financing round, led by Thrive Capital, with participation from GV and Alphabet. [6] Footprint : Google DeepMind provides one of the world’s largest AI research platforms, while Alphabet has global cloud, computing, data, and enterprise distribution. Isomorphic Labs is directly linked to Google DeepMind’s scientific work and uses AI for drug discovery. [6] Why they're in this category : Alphabet combines frontier-model capability with a dedicated drug-discovery company; Isomorphic Labs is the clearest incumbent-backed example of AI moving from biological prediction into therapeutic design. [6] Coverage : Reuters, “Google-backed AI drug discovery startup raises $600 million” — the financing established Isomorphic Labs as a major capitalized platform. [6]

NVIDIA

Stage : public (NASDAQ: NVDA) Funding : NVIDIA is publicly financed; its relevant category position comes through product investment, partnerships, and sales rather than venture funding. Footprint : NVIDIA is a global provider of accelerated computing and AI infrastructure, including platforms used for life-science and biomedical workloads. Why they're in this category : NVIDIA supplies the compute layer on which biological foundation models, molecular simulations, genomics pipelines, and AI-enabled laboratories are trained and deployed. Coverage : NVIDIA’s life-science position is best understood as infrastructure rather than a standalone biology application; the company’s Clara and scientific-computing initiatives illustrate that role.

Microsoft

Stage : public (NASDAQ: MSFT) Funding : Microsoft is publicly financed; relevant AI-for-biology activity is funded through its cloud, research, and strategic-partnership budgets. Footprint : Microsoft operates global cloud and enterprise software businesses serving pharmaceutical, healthcare, research, and biotechnology customers. Why they're in this category : Microsoft provides the enterprise cloud, data, security, and AI layer required to operationalize biological models inside regulated research organizations. Coverage : Microsoft is strategically significant because enterprise adoption often requires biology AI to run inside existing cloud, identity, compliance, and data environments rather than as a standalone tool.

Market Challengers

  • Isomorphic Labs — Google DeepMind-linked drug-discovery company that raised $600 million in its first external financing. [6]
  • Recursion — publicly traded, AI-native biotechnology company combining large-scale biological experiments with machine learning.
  • Exscientia — AI-driven drug-design company that became a public-market reference point for computational therapeutics.
  • Insilico Medicine — AI drug-discovery company combining target identification, molecular design, and an internal therapeutic pipeline; it reportedly raised a $110 million Series E. [3]
  • Generate — generative-AI biotechnology company focused on designing therapeutic proteins.
  • Terray Therapeutics — AI-enabled drug-discovery company using generative design and high-throughput experimentation; it closed a $120 million Series B. [3]
  • Owkin — machine-learning company focused on biomedical data, precision medicine, and federated learning.
  • Pathos AI — AI-enabled biotechnology company focused on oncology drug development; it raised $365 million in Series D financing. [1]

Isomorphic Labs

Stage : late-stage private; $600 million first external financing, March 2025 Funding : $600 million raised in the company’s first external financing round, led by Thrive Capital, with participation from GV and Alphabet. [6] Footprint : The company benefits from Google DeepMind’s research lineage, talent base, and strategic relationship with Alphabet. Its operating footprint is oriented toward pharmaceutical partnerships and internal drug-discovery programs. [6] Why they're in this category : Isomorphic Labs is a challenger because it packages frontier AI research into a dedicated therapeutic-development company; its ambiguity is that Alphabet backing gives it incumbent-level resources while its operating model remains a relatively young biotech platform. [6] Coverage : Reuters, “Google-backed AI drug discovery startup raises $600 million” — reports the landmark financing and Google relationship. [6]

Insilico Medicine

Stage : late-stage private, Series E Funding : Insilico secured $110 million in Series E financing, according to a sector review of AI foundation-model and drug-discovery companies. [3] Footprint : Insilico operates across AI platform development and an internal drug pipeline, giving it a broader footprint than a pure software vendor. [3] Why they're in this category : Insilico is a challenger because it combines target identification, generative molecular design, and therapeutic development rather than selling only a model or point solution. [3] Coverage : BioPharmaTrend, “17 Companies Pioneering AI Foundation Models in Pharma and Biotech” — places Insilico within the emerging foundation-model and AI-drug-discovery landscape. [3]

Terray Therapeutics

Stage : late-stage private, Series B Funding : Terray closed an oversubscribed $120 million Series B to expand its generative-AI pipeline and tNova platform. [3] Footprint : The company combines generative AI with high-throughput molecular experimentation, giving it both a software platform and a laboratory-generated data engine. [3] Why they're in this category : Terray’s differentiator is the coupling of computational molecular design with rapid experimental feedback, a model that can create proprietary data rather than relying only on public biological datasets. [3] Coverage : BioPharmaTrend, “17 Companies Pioneering AI Foundation Models in Pharma and Biotech” — reports the Series B and platform positioning. [3]

Market Innovators

  • Latent Labs — builds foundation models intended to make biology programmable; it emerged from stealth with $50 million. [7]
  • Bioptimus — develops universal biology foundation models and has reached $76 million in total funding. [2] [4]
  • Chai Discovery — develops AI models for molecular and protein-structure discovery; it initially raised nearly $30 million in seed funding. [3]
  • Helical — builds an open-source platform for DNA and RNA foundation models and raised €2.2 million in seed funding. [3]
  • EvolutionaryScale — develops large biological models for protein understanding and design.
  • Zymergen — pioneered computationally guided biological engineering, although its later corporate trajectory makes its placement as an early-stage innovator historically rather than currently relevant.
  • Profluent — applies generative models to protein and gene-editing design.
  • Enveda Biosciences — uses AI and metabolomics to discover therapeutics from natural products; it unveiled the PRISM foundation model trained on 1.2 billion mass spectra. [3]

Latent Labs

Stage : Series A, February 2025 Funding : $50 million total funding, including a $40 million Series A co-led by Radical Ventures and Sofinnova Partners, with participation from Flying Fish, Isomer, 8VC, Kindred Capital, and Pillar VC. [7] [8] Footprint : Latent Labs emerged from stealth and subsequently launched LatentX, a browser-based model for protein design intended for academic, biotech, and pharmaceutical users. [7] [5] Why they're in this category : Latent Labs is an innovator because it takes a contrarian “programmable biology” position: the core product is a general biology model and user-facing design environment, not a single therapeutic asset. [7] [5] Coverage : TechCrunch, “Latent Labs launches web-based AI model to democratize protein design” — covers the launch of LatentX and its intended users. [5]

Bioptimus

Stage : seed and follow-on financing; $76 million total by January 2025 Funding : Bioptimus reached $76 million in total funding, including a $41 million round led by Cathay Innovation, with participation from Sofinnova Partners, Bpifrance Large Venture, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, Sunrise, and angel investors. [2] Footprint : The company was founded by former Google DeepMind and Owkin scientists and released H-optimus-0, described as an open-source foundation model for pathology. [4] Why they're in this category : Bioptimus is an innovator because it is pursuing a universal biology-model layer spanning multiple biological modalities rather than building only a disease-specific application. [2] [4] Coverage : Sofinnova Partners, “Bioptimus” — summarizes the founding team, financing, and pathology-model release. [4]

Chai Discovery

Stage : early-stage private, seed Funding : Chai Discovery initially raised nearly $30 million in seed funding led by Thrive Capital and OpenAI, at an approximately $150 million valuation, according to a sector review. [3] Footprint : Chai is based in San Francisco and focuses on AI models for molecular and protein discovery. [3] Why they're in this category : Chai represents the model-native end of AI for Biology: its thesis is that specialized generative models can make molecular structure and interaction design accessible before a company builds a full therapeutic pipeline. [3] Coverage : BioPharmaTrend, “17 Companies Pioneering AI Foundation Models in Pharma and Biotech” — reports its initial financing and foundation-model positioning. [3]

Industry Coverage and Market Data

Market Reports

  • AI-ML Drug Discovery and Licensing R&D, M&A, Ventures and IPOs — 2025 Review — DealForma — sector transaction review covering venture rounds, licensing, M&A, and IPOs; it reports 348 financings and $11 billion in 2025 versus 264 rounds and $8.9 billion in 2024. [1]
  • 17 Companies Pioneering AI Foundation Models in Pharma and Biotech — BioPharmaTrend — company and financing survey focused on biology foundation models, protein design, RNA, mass spectrometry, and AI drug discovery. [3]
  • BIO Financial Report 2025 — Illinois Biotechnology Innovation Organization — investor and company landscape highlighting companies using AI in drug discovery, diagnostics, and programmable biology. [9]
  • AI for Drug Discovery Market — Grand View Research — relevant specialist market-report source, but the accessible search results did not expose enough report detail to responsibly quote its TAM, CAGR, geography, or forecast period.
  • Artificial Intelligence in Healthcare Market — MarketsandMarkets — broader healthcare-AI framing that can provide an upper-bound context, though it includes many applications outside biology and drug discovery.

Industry Articles

  • Latent Labs launches web-based AI model to democratize protein design — TechCrunch — reports LatentX’s browser-based protein-design workflow and the company’s backing. [5]
  • 17 Companies Pioneering AI Foundation Models in Pharma and Biotech — BioPharmaTrend — maps foundation-model companies across protein, RNA, pathology, mass spectrometry, and drug discovery. [3]
  • Bioptimus — Sofinnova Partners — investor perspective on the company’s founding team, model strategy, and pathology model. [4]
  • Latent Labs emerges from stealth, raising $50M for programmable biology — Tech.eu — frames programmable biology as the company’s category thesis and reports its financing. [8]
  • AI-ML Drug Discovery and Licensing R&D, M&A, Ventures and IPOs — 2025 Review — DealForma — provides a transaction-oriented view of the category’s maturation. [1]

Financial News Sources

  • Google-backed AI drug discovery startup raises $600 million — Reuters — reports Isomorphic Labs’ first external financing and Thrive Capital’s lead role. [6]
  • Latent Labs secures $50M in funding — Latent Labs — primary financing announcement detailing the $40 million Series A and syndicate. [7]
  • Bioptimus Hits $76M Funding Milestone — Business Wire — reports the company’s $41 million round and $76 million cumulative funding. [2]
  • Latent Labs emerges from stealth, raising $50M — Tech.eu — provides independent coverage of the financing and founding thesis. [8]
  • AI-ML Drug Discovery and Licensing R&D, M&A, Ventures and IPOs — 2025 Review — DealForma — reports financing concentration, IPO proceeds, M&A, and major rounds involving Isomorphic Labs, Pathos AI, and Lila Sciences. [1]
  • 17 Companies Pioneering AI Foundation Models in Pharma and Biotech — BioPharmaTrend — consolidates financing signals for Bioptimus, Chai Discovery, Helical, Insilico, Terray, and Enveda. [3]

Frontier and Open Questions

  • Will the category be defined by models or by clinical outcomes? Innovators such as Latent Labs, Bioptimus, and Chai Discovery are building reusable models, while challengers such as Insilico, Recursion, and Pathos AI are judged increasingly by validated therapeutic programs. [7] [2] [6] [3]
  • Can foundation models generate proprietary biological data, or will public pretraining remain sufficient? Terray’s model combines generative design with high-throughput experimentation, whereas model-first companies emphasize broad biological data and generalization. [3]
  • Will pharmaceutical companies buy horizontal platforms or prefer partnerships tied to specific assets? Isomorphic Labs’ large financing supports a platform strategy, but the sector’s commercial validation ultimately depends on licensing, milestones, and clinical progress. [6] [1]
  • Does automated experimentation belong inside AI for Biology or in a separate laboratory-robotics category? Lila Sciences and other AI–robotics companies push the boundary toward closed-loop discovery, while narrower definitions exclude physical laboratory infrastructure. [1]
  • Will open-source biology models commoditize the representation layer? Bioptimus’ open-source pathology model and Helical’s open-source DNA/RNA platform could lower entry barriers, shifting value toward proprietary data, workflow integration, and experimental execution. [4] [3]
  • Can early AI-generated molecules outperform conventional discovery after clinical attrition is included? The category has attracted substantial financing, but financing volume is not equivalent to clinical validation; challengers with internal pipelines will determine whether the market becomes a durable therapeutic-development model. [6] [1]

Adjacent Concepts and Categories

  • AI Drug Discovery — the narrower, therapeutics-focused subset of AI for Biology.
  • Biological Foundation Models — reusable models trained on protein, DNA, RNA, pathology, molecular, or multimodal data.
  • Generative Protein Design — computational creation and optimization of proteins, antibodies, enzymes, and other biologics.
  • Self-Driving Laboratories — automated systems that select, execute, and learn from biological experiments.
  • Scientific Data Infrastructure — data management, provenance, governance, and retrieval systems that make biological AI usable.
  • Computational Biology — the established analytical discipline from which modern biology-AI applications emerged.
  • Precision Medicine — patient-level diagnostics and treatment selection enabled by biological data and machine learning.
  • Synthetic Biology — engineering biological systems, often using AI to design sequences, pathways, and experimental programs.

Sources

[1] 2026, Jan 13. dealforma.com . AI-ML Drug Discovery and Licensing R&D, M&A, Ventures and IPOs - 2025 ... . Updated: 2026, Nov 07. Generated: 2026, Nov 09. Perplexity API response.

[2] 2025, Jan 14. Business Wire . Bioptimus Hits $76M Funding Milestone and Prepares to ... . Updated: 2026, Oct 11. Generated: 2026, Nov 09. Perplexity API response.

[3] 2024, Jun 19. biopharmatrend.com . 17 Companies Pioneering AI Foundation Models in Pharma and ... . Updated: 2026, Oct 27. Generated: 2026, Nov 09. Perplexity API response.

[4] 2024, Feb 20. sofinnovapartners.com . Bioptimus . Updated: 2026, Nov 09. Generated: 2026, Nov 09. Perplexity API response.

[5] 2025, Jul 21. TechCrunch . Latent Labs launches web-based AI model to democratize protein design | TechCrunch . Updated: 2026, Nov 03. Generated: 2026, Nov 09. Perplexity API response.

[6] 2025, Mar 31. Reuters . Google-backed AI drug discovery startup raises $600 million . Updated: 2026, Oct 01. Generated: 2026, Nov 09. Perplexity API response.

[7] 2025, Feb 13. latentlabs.com . Latent Labs secures $50M in funding to realize the potential ... . Updated: 2026, Oct 02. Generated: 2026, Nov 09. Perplexity API response.

[9] ibio.org . member investor portfolio report - 2025 . Updated: 2026, Nov 05. Generated: 2026, Nov 09. Perplexity API response.

[10] 2025, Nov 10. axios.com . Clio's $5b valuation, Klook's IPO, and Valar Atomics' giant A . Updated: 2026, Oct 26. Generated: 2026, Nov 09. Perplexity API response.